Transurethral microwave thermotherapy: what role should it play versus medical management in the treatment of benign prostatic hyperplasia?
Both transurethral microwave thermotherapy (TUMT) and medical management by alpha-blockade or 5-alpha-reductase inhibition are increasingly being considered as alternatives to surgery for treatment of patients with benign prostatic hyperplasia (BPH). We review current evidence supporting the effectiveness and safety of TUMT and medical management. Factors for consideration in appropriately selecting patients for TUMT versus medical management are suggested. Available data indicate that TUMT confers greater long-term benefits than medical management as judged by symptom score and peak urinary flow rate improvements. TUMT-associated morbidity is comparatively low. Alpha-blockade affords more rapid relief than TUMT for patients with BPH; however, other strategies such as the use of temporary intraurethral endoprostheses during the acute post-TUMT recovery period may diminish or abolish the differences in time-course of symptom and flow rate improvement between TUMT and alpha-blockade. 5-Alpha-reductase inhibition with finasteride offers a favorable side-effect profile, although the magnitude of symptom and flow rate improvements is modest, and maximal effects of finasteride do not become manifest until after several months of treatment. As TUMT continues to evolve, increasing attention is being accorded the delivery of high thermal doses and precise targeting of the thermal energy delivered. The development of alpha-blockers with a more favorable side-effect profile continues to be a major focus of investigation. The potential clinical utility of combination therapy with TUMT and alpha-blockade is currently under investigation.
Djavan
B
B
Department of Urology, University of Vienna, Austria.
Larson
T R
TR
Blute
M L
ML
Marberger
M
M
D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003972:Diathermy / Q000009:adverse effects / Q000379:methods; D006801:Humans; D008297:Male; D008872:Microwaves / Q000627:therapeutic use*; D010146:Pain / Q000209:etiology; D011470:Prostatic Hyperplasia / Q000628:therapy*; D014521:Urethra; D016055:Urinary Retention / Q000209:etiology